A Paradigm Shift and New Therapeutic Options for the Metabolic Syndrome
The metabolic syndrome, characterized by obesity, dyslipidemia, insulin resistance and hypertension, increases the risk of cardiovascular morbidity and mortality. Most current views on the pathogenesis of the metabolic syndrome and its existing treatments have been dominated by a glucocentric approach: the glycemic response to insulin is suboptimal, with dire metabolic consequences. Such consequences are compensatory hyperinsulinemia, ?? cell glucotoxicity and lipotoxicity and the deposition of amyloid in pancreatic islets, with concomitant inflammation, endothelial dysfunction, a procoagulant state and dyslipidemia. In addition, these views have been applied on the premise that effector molecules involved in disease pathogenesis or response to therapy are invariant across the population.However, most current therapies have limited efficacy and limited tolerability.
LicenseAuthors who publish with this journal agree to the following terms:
a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).